{"id":"paclitaxel-trastuzumab","safety":{"commonSideEffects":[{"rate":"40-60%","effect":"Neutropenia"},{"rate":"30-50%","effect":"Fatigue"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1201585","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Paclitaxel's mechanism of action involves the stabilization of microtubules, preventing their disassembly and thereby inhibiting cell division. This leads to cell cycle arrest and apoptosis in rapidly dividing cancer cells. Trastuzumab, on the other hand, is a monoclonal antibody that binds to the HER2/neu receptor, which is overexpressed in certain breast cancer cells. This binding triggers antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, ultimately leading to the death of cancer cells.","oneSentence":"Paclitaxel works by inhibiting microtubule dynamics, thereby inducing cell cycle arrest and apoptosis in rapidly dividing cancer cells. Trastuzumab targets the HER2/neu receptor, which is overexpressed in certain breast cancer cells, and triggers antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:28.391Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of node-positive breast cancer"},{"name":"First-line treatment of HER2-positive metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT05256225","phase":"PHASE3","title":"Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-16","conditions":"Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma","enrollment":360},{"nctId":"NCT07060807","phase":"PHASE3","title":"A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-21","conditions":"Breast Neoplasms","enrollment":1000},{"nctId":"NCT04266249","phase":"PHASE2","title":"CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-03-13","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8","enrollment":2175},{"nctId":"NCT02654119","phase":"PHASE2","title":"Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2015-12-11","conditions":"HER2 Positive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7","enrollment":20},{"nctId":"NCT05143970","phase":"PHASE1","title":"A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Institut Paoli-Calmettes","startDate":"2022-01-21","conditions":"Metastatic Cancer, Metastatic Breast Cancer, Metastatic Pancreatic Cancer","enrollment":27},{"nctId":"NCT07203729","phase":"PHASE2","title":"The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-03-01","conditions":"HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis","enrollment":184},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT04001829","phase":"PHASE2","title":"Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-08-09","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8","enrollment":249},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT06989112","phase":"PHASE3","title":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-27","conditions":"Endometrial Cancer","enrollment":600},{"nctId":"NCT07102381","phase":"PHASE2","title":"A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Jazz Pharmaceuticals","startDate":"2025-09-24","conditions":"HER2-positive Breast Cancer, Breast Cancer","enrollment":125},{"nctId":"NCT04931342","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-07","conditions":"Ovarian Cancer","enrollment":176},{"nctId":"NCT05733689","phase":"PHASE1","title":"Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2025-06-27","conditions":"Gastroesophageal Adenocarcinoma","enrollment":20},{"nctId":"NCT04494425","phase":"PHASE3","title":"Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-07-24","conditions":"Advanced or Metastatic Breast Cancer","enrollment":866},{"nctId":"NCT05325632","phase":"PHASE2","title":"Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-10-28","conditions":"HER2-positive Breast Cancer","enrollment":53},{"nctId":"NCT07053085","phase":"PHASE2","title":"A Study of Surgery and Radiotherapy in People With Breast Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-09-17","conditions":"Metastatic Breast Cancer, HER2-positive Breast Cancer","enrollment":162},{"nctId":"NCT07421141","phase":"PHASE2","title":"De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Radiological Centre of the Ministry of Health of Russia","startDate":"2023-09-01","conditions":"Breast Cancer, HER2-positive Breast Cancer, Early Breast Cancer","enrollment":186},{"nctId":"NCT07377643","phase":"PHASE3","title":"IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.","startDate":"2026-02-10","conditions":"HER2-positive Breast Cancer","enrollment":540},{"nctId":"NCT04893109","phase":"PHASE2","title":"ATEMPT 2.0: Adjuvant T-DM1 vs TH","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-06-16","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":500},{"nctId":"NCT03179904","phase":"PHASE2","title":"TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-08-03","conditions":"Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8","enrollment":17},{"nctId":"NCT07315880","phase":"","title":"Extracellular Fluid Changes During Neoadjuvant Chemotherapy","status":"COMPLETED","sponsor":"Florence Nightingale Hospital, Istanbul","startDate":"2021-01-01","conditions":"Lymphedema Arm","enrollment":111},{"nctId":"NCT05113251","phase":"PHASE3","title":"Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-10-25","conditions":"Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer","enrollment":927},{"nctId":"NCT04784715","phase":"PHASE3","title":"Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-04-26","conditions":"Breast Cancer; HER2-positive; Metastatic","enrollment":1157},{"nctId":"NCT06446882","phase":"NA","title":"Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Fundacio Clinic Barcelona","startDate":"2024-10-11","conditions":"HER2-positive Breast Cancer, Early-stage Breast Cancer","enrollment":304},{"nctId":"NCT04644068","phase":"PHASE1, PHASE2","title":"Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-11-12","conditions":"Ovarian Cancer, Breast Cancer, Pancreatic Cancer","enrollment":702},{"nctId":"NCT01853748","phase":"PHASE2","title":"T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-05","conditions":"Breast Cancer","enrollment":512},{"nctId":"NCT01196390","phase":"PHASE3","title":"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02-14","conditions":"Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Cancer AJCC v7","enrollment":203},{"nctId":"NCT05945732","phase":"","title":"DESTINY Breast Respond HER2-low Europe","status":"RECRUITING","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2023-10-24","conditions":"Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer","enrollment":1155},{"nctId":"NCT03101748","phase":"PHASE1, PHASE2","title":"Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-02-19","conditions":"Breast Inflammatory Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma","enrollment":34},{"nctId":"NCT05993234","phase":"","title":"A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)","status":"RECRUITING","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2023-12-05","conditions":"HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma","enrollment":257},{"nctId":"NCT06135714","phase":"PHASE3","title":"Metastasis-directed Therapy for Oligometastases of Breast Cancer","status":"RECRUITING","sponsor":"Tokyo Medical and Dental University","startDate":"2023-11-08","conditions":"Breast Cancer, Oligometastasis, Metastatic Breast Cancer","enrollment":340},{"nctId":"NCT05415215","phase":"PHASE3","title":"A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-07-05","conditions":"Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer","enrollment":346},{"nctId":"NCT07393425","phase":"PHASE2","title":"Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2026-02-02","conditions":"HER2 + Breast Cancer","enrollment":50},{"nctId":"NCT07389876","phase":"","title":"Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-09-01","conditions":"Gastric Cancer, Second-line Treatment","enrollment":250},{"nctId":"NCT01796197","phase":"PHASE2","title":"Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-08","conditions":"Breast Cancer","enrollment":23},{"nctId":"NCT06771622","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"FBD Biologics Limited","startDate":"2025-03-13","conditions":"Solid Cancer","enrollment":500},{"nctId":"NCT07022483","phase":"PHASE3","title":"Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-09-30","conditions":"Endometrial Cancer","enrollment":710},{"nctId":"NCT07007559","phase":"PHASE1, PHASE2","title":"ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies","status":"RECRUITING","sponsor":"ALX Oncology Inc.","startDate":"2025-04-28","conditions":"Breast Cancer, Metastatic","enrollment":80},{"nctId":"NCT07383818","phase":"PHASE2","title":"Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2026-02-01","conditions":"HR Positive/HER2 Low Breast Cancer","enrollment":111},{"nctId":"NCT06340568","phase":"PHASE3","title":"A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-06-10","conditions":"Endometrial Cancer","enrollment":480},{"nctId":"NCT03742102","phase":"PHASE1, PHASE2","title":"A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-12-21","conditions":"Triple Negative Breast Neoplasms","enrollment":243},{"nctId":"NCT07340398","phase":"PHASE2","title":"Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-12-25","conditions":"HER2-positive Early Breast Cancer","enrollment":200},{"nctId":"NCT05296798","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-07-18","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":922},{"nctId":"NCT07340164","phase":"PHASE2","title":"Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2025-12-30","conditions":"Ovarian Cancer, Ovarian Carcinoma, Recurrent, Ovarian Cancer Metastatic Recurrent","enrollment":116},{"nctId":"NCT04704934","phase":"PHASE3","title":"Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2021-05-21","conditions":"Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":490},{"nctId":"NCT04290793","phase":"PHASE2, PHASE3","title":"Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2020-03-01","conditions":"Breast Cancer","enrollment":113},{"nctId":"NCT04578106","phase":"PHASE2","title":"Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy","status":"TERMINATED","sponsor":"Fundacio Clinic Barcelona","startDate":"2020-09-23","conditions":"HER2-positive Breast Cancer, Stage I Breast Cancer","enrollment":5},{"nctId":"NCT06536556","phase":"","title":"Effects of a Single Chemotherapy Administration on Skeletal Muscle of Breast Cancer Patients: Comparison of Paclitaxel vs Paclitaxel + Trastuzumab vs Paclitaxel + Carboplatine: the PROTECT-06 Bis Study","status":"TERMINATED","sponsor":"Institut de cancérologie Strasbourg Europe","startDate":"2024-05-02","conditions":"Breast Cancer","enrollment":5},{"nctId":"NCT07317778","phase":"PHASE2","title":"Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-15","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer","enrollment":249},{"nctId":"NCT05803889","phase":"","title":"Characterization and Kinetic of Chemotherapy-induced Cardiovascular Toxicity in Breast Cancer","status":"TERMINATED","sponsor":"Institut de cancérologie Strasbourg Europe","startDate":"2023-09-21","conditions":"Breast Cancer","enrollment":2},{"nctId":"NCT03199885","phase":"PHASE3","title":"Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-05","conditions":"Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma, Recurrent Breast Adenocarcinoma","enrollment":190},{"nctId":"NCT06996548","phase":"","title":"Sarcopenia and Paclitaxel-Induced Neuropathy in Early Stage Breast Cancer (Neuro-Sarc)","status":"COMPLETED","sponsor":"Gazi University","startDate":"2024-11-01","conditions":"Sarcopenia, Paclitaxel Induced Neuropathy, Breast Carcinoma","enrollment":120},{"nctId":"NCT05256745","phase":"PHASE1, PHASE2","title":"RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer","status":"RECRUITING","sponsor":"Georgetown University","startDate":"2023-06-06","conditions":"Cancer Related Cognitive Decline, Non-metastatic Breast Cancer","enrollment":48},{"nctId":"NCT00781612","phase":"PHASE2","title":"A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2008-10-16","conditions":"Neoplasm Metastasis","enrollment":720},{"nctId":"NCT07216105","phase":"PHASE1","title":"FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Fate Therapeutics","startDate":"2025-11-04","conditions":"Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer","enrollment":113},{"nctId":"NCT04556773","phase":"PHASE1","title":"A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-12-17","conditions":"Metastatic Breast Cancer","enrollment":138},{"nctId":"NCT04538742","phase":"PHASE1, PHASE2","title":"A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-12-28","conditions":"Metastatic Breast Cancer","enrollment":245},{"nctId":"NCT07176702","phase":"PHASE2","title":"A Phase II Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-09-30","conditions":"Metastatic PDAC, HER2-positive Status","enrollment":45},{"nctId":"NCT07150767","phase":"PHASE1","title":"A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer","status":"WITHDRAWN","sponsor":"Beijing Bio-Targeting Therapeutics Technology Co., Ltd","startDate":"2025-03-26","conditions":"Locally Advanced Breast Cancer (LABC)","enrollment":""},{"nctId":"NCT06843681","phase":"PHASE2","title":"Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study","status":"ENROLLING_BY_INVITATION","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-03-01","conditions":"Breast Carcinoma in Situ","enrollment":54},{"nctId":"NCT01358877","phase":"PHASE3","title":"A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11-08","conditions":"Breast Cancer","enrollment":4804},{"nctId":"NCT04193059","phase":"PHASE3","title":"Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2019-12-20","conditions":"Breast Cancer","enrollment":1560},{"nctId":"NCT03571633","phase":"PHASE2","title":"Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Leon Berard","startDate":"2018-08-06","conditions":"HER2-positive Breast Cancer, Operable Breast Cancer","enrollment":90},{"nctId":"NCT07245797","phase":"PHASE2","title":"A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC","status":"NOT_YET_RECRUITING","sponsor":"Zhimin Shao","startDate":"2025-12-15","conditions":"Breast Cancer","enrollment":164},{"nctId":"NCT07239271","phase":"PHASE3","title":"A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation Model","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-11-16","conditions":"Patients With HER2-positive Breast Cancer (BC) Suitable for Neoadjuvant Therapy","enrollment":2000},{"nctId":"NCT03498521","phase":"PHASE2","title":"A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-07-10","conditions":"Cancer of Unknown Primary Site","enrollment":529},{"nctId":"NCT06328738","phase":"PHASE1","title":"ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Enliven Therapeutics","startDate":"2024-05-30","conditions":"HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors","enrollment":275},{"nctId":"NCT04425018","phase":"PHASE2","title":"MARGetuximab Or Trastuzumab (MARGOT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-07-13","conditions":"Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer","enrollment":174},{"nctId":"NCT01750073","phase":"PHASE2","title":"Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Nebraska","startDate":"2012-12-07","conditions":"Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative","enrollment":92},{"nctId":"NCT04329065","phase":"PHASE2","title":"Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2022-04-20","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8","enrollment":25},{"nctId":"NCT07213206","phase":"PHASE3","title":"CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-10-07","conditions":"Breast Cancer","enrollment":1500},{"nctId":"NCT03734029","phase":"PHASE3","title":"Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2018-12-27","conditions":"Breast Cancer","enrollment":557},{"nctId":"NCT03264547","phase":"PHASE3","title":"A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab","status":"COMPLETED","sponsor":"Japan Breast Cancer Research Group","startDate":"2017-08-28","conditions":"Breast Cancer","enrollment":446},{"nctId":"NCT00295893","phase":"PHASE2","title":"Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2005-09-27","conditions":"Breast Cancer","enrollment":121},{"nctId":"NCT03716180","phase":"PHASE1","title":"DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-11-05","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT04126525","phase":"PHASE2","title":"Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"RenJi Hospital","startDate":"2019-06-18","conditions":"Breast Cancer Female","enrollment":53},{"nctId":"NCT02514681","phase":"PHASE3","title":"A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer","status":"COMPLETED","sponsor":"Japan Breast Cancer Research Group","startDate":"2015-08-01","conditions":"HER2-positive Locally Advanced or Metastatic Breast Cancer","enrollment":226},{"nctId":"NCT05900206","phase":"PHASE2","title":"Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2023-10-26","conditions":"Breast Cancer","enrollment":370},{"nctId":"NCT07095023","phase":"NA","title":"Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-08-15","conditions":"Breast Cancers","enrollment":112},{"nctId":"NCT05582499","phase":"PHASE2","title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-01","conditions":"Breast Neoplasm, Breast Cancer, Breast Tumors","enrollment":716},{"nctId":"NCT00770809","phase":"PHASE3","title":"Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-02-24","conditions":"Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7","enrollment":305},{"nctId":"NCT07115095","phase":"NA","title":"Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer","status":"COMPLETED","sponsor":"Nanlin Li","startDate":"2021-01-01","conditions":"HER2-positive Breast Cancer","enrollment":98},{"nctId":"NCT05002127","phase":"PHASE2, PHASE3","title":"A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)","status":"ACTIVE_NOT_RECRUITING","sponsor":"ALX Oncology Inc.","startDate":"2022-01-15","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma","enrollment":127},{"nctId":"NCT06973525","phase":"PHASE2","title":"This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy.","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-09-01","conditions":"HER2-positive Breast Cancer","enrollment":30},{"nctId":"NCT03013218","phase":"PHASE1","title":"A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)","status":"COMPLETED","sponsor":"ALX Oncology Inc.","startDate":"2017-02-03","conditions":"Metastatic Cancer, Solid Tumor, Advanced Cancer","enrollment":174},{"nctId":"NCT07093931","phase":"PHASE4","title":"Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-08-01","conditions":"Breast Cancer","enrollment":468},{"nctId":"NCT06992882","phase":"PHASE3","title":"A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-07-08","conditions":"HER2-positive Breast Cancer","enrollment":2306},{"nctId":"NCT06441890","phase":"PHASE2","title":"BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2024-12-05","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":28},{"nctId":"NCT07062263","phase":"PHASE3","title":"Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients","status":"RECRUITING","sponsor":"Tata Memorial Centre","startDate":"2023-07-21","conditions":"Biliary Tract Cancer, HER2-positive Cancer, Advanced Cancer","enrollment":220},{"nctId":"NCT01275677","phase":"PHASE3","title":"Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02-08","conditions":"HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma","enrollment":3270},{"nctId":"NCT02436993","phase":"PHASE2","title":"Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Irvine","startDate":"2015-04","conditions":"Breast Carcinoma","enrollment":120},{"nctId":"NCT07057427","phase":"PHASE3","title":"Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2025-06-24","conditions":"Breast Cancer","enrollment":812},{"nctId":"NCT03747120","phase":"PHASE2","title":"Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2019-01-25","conditions":"HER2-positive Breast Cancer, Breast Cancer","enrollment":138},{"nctId":"NCT06439693","phase":"PHASE2","title":"The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-08-08","conditions":"Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic","enrollment":72},{"nctId":"NCT06927180","phase":"PHASE2","title":"SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2025-04-16","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3)","enrollment":180},{"nctId":"NCT01730833","phase":"PHASE2","title":"Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2013-07-17","conditions":"HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIA Breast Cancer","enrollment":63},{"nctId":"NCT02314481","phase":"PHASE2","title":"Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College, London","startDate":"2017-05-12","conditions":"Non-small Cell Lung Cancer","enrollment":50},{"nctId":"NCT06975475","phase":"PHASE2","title":"SHR-A1811 and THPy in First or Second Line for HER2 Positive Advanced Breast Cancer Brain Metastases","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-06-01","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT05311176","phase":"PHASE2","title":"A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)","status":"TERMINATED","sponsor":"Imugene Limited","startDate":"2022-08-17","conditions":"Gastric Cancer, Cancer of Stomach, Gastric Adenocarcinoma","enrollment":7}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":112,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Paclitaxel + Trastuzumab","genericName":"Paclitaxel + Trastuzumab","companyName":"Institut de cancérologie Strasbourg Europe","companyId":"institut-de-canc-rologie-strasbourg-europe","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Paclitaxel works by inhibiting microtubule dynamics, thereby inducing cell cycle arrest and apoptosis in rapidly dividing cancer cells. Trastuzumab targets the HER2/neu receptor, which is overexpressed in certain breast cancer cells, and triggers antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Used for Adjuvant treatment of node-positive breast cancer, First-line treatment of HER2-positive metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}